We demonstrated that the Gal-1 gene dosage did not affect tumour incidence, growth rate, or survival probability, but was correlated with alterations in the immune phenotype exemplified by a reduction of CD4+ T cell infiltration in tumours of Gal-1−/− mice [45]. This evidence concerns the gene CD4 and neoplasm.